SCHEMBL3574150

SCHEMBL3574150

Cc1ncc(NC(=O)NCc2ccccc2Cl)cc1C#Cc1cnc(NCCN2CCOCC2)nc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.45
LCK P06239 1/20 0.41
MAPK14 Q16539 1/20 0.41
CNR1 P21554 1/20 0.41
ALDH1A1 P00352 4/20 0.40
P2RX7 Q99572 1/20 0.40
MAPT P10636 1/20 0.40
RIPK1 Q13546 1/20 0.39
RIPK3 Q9Y572 1/20 0.39
MAPK8 P45983 1/20 0.39
FLT3 P36888 1/20 0.39
LMNA P02545 3/20 0.39
CYP1A2 P05177 2/20 0.39
TSHR P16473 2/20 0.39
CYP2C19 P33261 2/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
HIF1A Q16665 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3581924 0.91 CNR2 (0.43) SMN1; SMN2LCKMAPK14ALDH1A1MAPT
SCHEMBL3663799 0.91 LCK (0.40) SMN1; SMN2LCKMAPK14CNR1RIPK1
SCHEMBL5276497 0.88 SMN1; SMN2 (0.48) SMN1; SMN2CNR1ALDH1A1MAPTMAPK8
SCHEMBL3579827 0.85 AURKA (0.43) LCKMAPK14RIPK1RIPK3LMNA
SCHEMBL3577243 0.82 LCK (0.45) SMN1; SMN2LCKMAPK14CNR1MAPT
SCHEMBL3585208 0.82 LCK (0.43) LCKMAPK14ALDH1A1MAPTRIPK1
SCHEMBL3575312 0.79 NAMPT (0.39) SMN1; SMN2LCKMAPK14CNR1RIPK1
SCHEMBL3580884 0.77 MCHR1 (0.45) SMN1; SMN2LCKMAPK14ALDH1A1MAPT
SCHEMBL3575970 0.76 AURKA (0.46) SMN1; SMN2CNR1ALDH1A1FLT3LMNA
SCHEMBL4639012 0.75 LCK (0.50) LCKMAPK14RIPK1RIPK3MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048543-A1 PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY ASTRAZENECA AB (SE) 2010-02-25 US disclosed
US-20100048543-A1 PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY ASTRAZENECA AB (SE) 2010-02-25 US disclosed
US-20100048543-A1 PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY ASTRAZENECA AB (SE) 2010-02-25 US disclosed
EP-1863805-A1 PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY AstraZeneca AB (SE) 2007-12-12 EP disclosed
WO-2006082373-A1 PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY ASTRAZENECA AB (SE) 2006-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048543-A1 PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY TEK, TYMP, TIE1 SMN1; SMN2 3824/4885LCK 326/4885MAPK14 1894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.